`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________
`
`PFIZER, INC. and
`SAMSUNG BIOEPIS CO., LTD.,1
`Petitioners,
`
`v.
`
`GENENTECH, INC.,
`Patent Owner,
`____________
`
`IPR2017-01489
`Patent No. 6,407,213
`____________
`
`
`PETITIONER PFIZER’S UPDATED MANDATORY NOTICES
`
`
`1 Samsung Bioepis Co., Ltd.’s IPR2017-02140 has been joined with this
`
`proceeding. (IPR2017-02140, Paper 40.)
`
`
`
`
`
`IPR2017-01489
`Petitioner Pfizer’s Updated Mandatory Notices
`
`
`In accordance with 37 C.F.R. §§ 42.8(a)(3), (b)(2) and (b)(3), Petitioner Pfizer
`
`hereby submits the following updated mandatory notices:
`
`A.
`
`37 C.F.R. § 42.8(b)(2): Related Matters
`
`Petitioner concurrently filed an IPR petition for claims of U.S. Patent No.
`
`6,407,213 (IPR2017-01488).
`
`The ’213 patent is the subject of two earlier IPR proceedings filed by third-
`
`party Mylan Pharmaceuticals Inc.: IPR2016–01693 and IPR2016–01694. These
`
`proceedings were terminated by the Board on March 10, 2017 after the parties filed
`
`a Joint Motion to Terminate. Paper No. 24, IPR2016–01693; Paper No. 23,
`
`IPR2016–01694 (March 10, 2017).
`
`The ’213 patent is also the subject of IPR2017-01373, IPR2017-01374,
`
`IPR2017-02031, IPR2017-02032, IPR2017-02139, and IPR2017-02140. Petitioner
`
`is not a party to those proceedings.
`
`The ’213 patent is also at issue in Amgen Inc v. Genentech, Inc. et al., No. 2-
`
`17-cv-07349 (C.D. Cal.); Genentech, Inc. et al. v. Amgen Inc., No. 1-17-cv-01407
`
`(D. Del.); Genentech, Inc. et al. v. Amgen Inc., No. 1-17-cv-01471 (D. Del.);
`
`Celltrion, Inc. et al. v. Genentech, Inc. et al., No. 3-18-cv-00274 (N.D. Cal.);
`
`Genentech, Inc. et al. v. Celltrion, Inc. et al., No. 1-18-cv-00095 (D. Del.);
`
`Genentech, Inc. et al. v. Amgen, Inc., No. 1-18-cv-00924 (D. Del.); and Genentech,
`
`1
`
`
`
`
`IPR2017-01489
`Petitioner Pfizer’s Updated Mandatory Notices
`
`Inc. et al. v. Celltrion, Inc. et al., No. 1-18-cv-01025(D. Del.). Petitioner is not a
`
`party to these proceedings.
`
`Patent Owner has asserted the ’213 patent against Petitioner in Genentech,
`
`Inc. v. Pfizer, Inc., No. 1-17-cv-01672 (D. Del.), filed November 17, 2017.
`
`Petitioner is not aware of any other judicial or administrative matters that
`
`would affect, or be affected by, a decision in the proceeding.
`
`B.
`
`37 C.F.R. § 42.8(b)(3): Lead and Back-Up Counsel
`
`Lead Counsel
`Amanda Hollis (Reg. No. 55,629)
`amanda.hollis@kirkland.com
`
`Postal and Hand-Delivery Address:
`
`KIRKLAND & ELLIS LLP
`300 North LaSalle
`Chicago, IL 60654
`Telephone: (312) 862-2011
`Facsimile:
`(312) 862-2200
`
`Back-up Counsel
`Benjamin A. Lasky (pro hac vice)
`benjamin.lasky@kirkland.com
`
`Stefan Miller, Ph.D. (Reg. No. 57,623)
`stefan.miller@kirkland.com
`
`Sarah K. Tsou (pro hac vice)
`sarah.tsou@kirkland.com
`
`Mark C. McLennan (pro hac vice)
`mark.mclennan@kirkland.com
`
`Christopher J. Citro (pro hac vice)
`christopher.citro@kirkland.com
`
`Micah Rappazzo (Reg. No. 75,085)
`micah.rappazzo@kirkland.com
`
`Postal and Hand-Delivery Address:
`
`KIRKLAND & ELLIS LLP
`601 Lexington Avenue
`New York, NY 10022
`Telephone: (212) 446-4800
`2
`
`
`
`
`IPR2017-01489
`Petitioner Pfizer’s Updated Mandatory Notices
`
`Lead Counsel
`
`
`
`
`Date: July 12, 2018
`
`
`
`
`
`Back-up Counsel
`Facsimile:
`(212) 446-4900
`
`Sharick Naqi (pro hac vice pending)
`sharick.naqi@kirkland.com
`
`Postal and Hand-Delivery Address:
`
`KIRKLAND & ELLIS LLP
`300 North LaSalle
`Chicago, IL 60654
`Telephone: (312) 862-2011
`Facsimile:
`(312) 862-2200
`
`Karen Younkins (Reg. No. 67,554)
`(request for withdrawal pending)
`karen.younkins@kirkland.com
`
`Postal and Hand-Delivery Address:
`
`KIRKLAND & ELLIS LLP
`333 South Hope Street
`Los Angeles, CA 90071
`Telephone: (213) 680-8140
`Facsimile:
`(213) 680-8500
`
`Respectfully submitted,
`
` /Amanda Hollis/
`Amanda Hollis (Reg. No. 55,629)
`Attorney For Petitioner Pfizer, Inc.
`
`3
`
`
`
`
`IPR2017-01489
`Petitioner Pfizer’s Updated Mandatory Notices
`
`
`CERTIFICATE OF SERVICE
`The undersigned hereby certifies that a copy of the foregoing Updated Notices
`
`was served on July 12, 2018, via electronic service on lead and back-up counsel:
`
`For Genentech, Inc.
`david.cavanaugh@wilmerhale.com
`lauren.blakely@wilmerhale.com
`robert.gunther@wilmerhale.com
`abrausa@durietangri.com
`ddurie@durietangri.com
`andrew.danford@wilmerhale.com
`kevin.prussia@wilmerhale.com
`lisa.pirozzolo@wilmerhale.com
`
`For Samsung Bioepis Co., Ltd.:
`ddrivas@whitecase.com
`sweingaertner@whitecase.com
`eric.majchrzak@whitecase.com
`athakore@whitecase.com
`
`
`
` /Amanda Hollis/
`Amanda Hollis
`
`4
`
`
`